SRR25617898
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.380
- PROTEIN_SECRETION+0.360
- INTERFERON_ALPHA_RESPONSE+0.320
- UV_RESPONSE_DN+0.320
- TGF_BETA_SIGNALING+0.280
- ANGIOGENESIS+0.240
- INTERFERON_GAMMA_RESPONSE+0.180
- APICAL_JUNCTION+0.160
- NOTCH_SIGNALING+0.150
- ESTROGEN_RESPONSE_EARLY+0.130
Top 10 suppressed
- MYC_TARGETS_V2-0.560
- MYC_TARGETS_V1-0.390
- E2F_TARGETS-0.370
- G2M_CHECKPOINT-0.350
- MTORC1_SIGNALING-0.350
- UNFOLDED_PROTEIN_RESPONSE-0.340
- PANCREAS_BETA_CELLS-0.330
- UV_RESPONSE_UP-0.310
- TNFA_SIGNALING_VIA_NFKB-0.270
- GLYCOLYSIS-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E9-A1RI-01A-11R-A169-07 | — | A | 0.794 |
| 2 | SRR6013583 | — | cohortA1 | 0.761 |
| 3 | 2b1fa47d-360a-4b4a-aa11-23bdb025b559 | — | — | 0.760 |
| 4 | MNG946 | — | — | 0.732 |
| 5 | ERR2208916 | — | — | 0.730 |
| 6 | SAMN03290900 | — | — | 0.729 |
| 7 | TCGA-05-4405-01A-21R-1858-07 | — | cohortA1 | 0.725 |
| 8 | SRR6013588 | — | cohortA1 | 0.723 |
| 9 | TCGA-50-5944-01A-11R-1755-07 | — | cohortA1 | 0.720 |
| 10 | TCGA-B6-A0RP-01A-21R-A084-07 | — | B | 0.719 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.380 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.360 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.320 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.320 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.280 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.240 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.180 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.160 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.150 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.130 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.110 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.070 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.060 | Remibrutinib | — uncovered |
| COAGULATION | 0.050 | Binimetinib | — uncovered |
| MYOGENESIS | 0.050 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.050 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |